Journal
CNS NEUROSCIENCE & THERAPEUTICS
Volume 16, Issue 1, Pages 45-50Publisher
WILEY
DOI: 10.1111/j.1755-5949.2009.00120.x
Keywords
Alcohol dependence; Benzodiazepines dependence; Clinical trials; Pregabalin; Withdrawal syndrome
Categories
Ask authors/readers for more resources
We review all available studies on the use of the newer anticonvulsant drug pregabalin (PGB) in the treatment of both alcohol dependence (AD) and benzodiazepine dependence (BD). In AD, the available evidence includes one open-label and one double-blind randomized studies, whereas in BD, only a few case reports and one open-label study are as yet available. In both conditions, PGB was found efficacious with significant improvement in withdrawal symptoms at the dosage ranges of 150-450 mg/day (AD) and 225-900 mg/day (BD). Moreover, its side effects were mild and transient. Despite the limited quality of the studies design, their findings suggest that PGB might constitute a novel efficacious and safe option in the treatment of both AD and BD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available